Papers authored by Willis SN

Collect these papers and discover other ones on Labmeeting. Learn more.
Epstein-Barr virus infection is not a characteristic feature of multiple sclerosis brain.
+ cite this
+ View Abstract
Willis SN, Stadelmann C, Rodig SJ, Caron T, Gattenloehner S, Mallozzi SS, Roughan JE, Almendinger SE, Blewett MM, Brück W, Hafler DA, and O'Connor KC
Brain : a journal of neurology 132(Pt 12):3318-28, 2009 Dec - Who cited this? | PubMed ID: 19638446 | Fulltext
Recommend
The microenvironment of germ cell tumors harbors a prominent antigen-driven humoral response.
+ cite this
+ View Abstract
Willis SN, Mallozzi SS, Rodig SJ, Cronk KM, McArdel SL, Caron T, Pinkus GS, Lovato L, Shampain KL, Anderson DE, Anderson RC, Bruce JN, and O'Connor KC
Journal of immunology (Baltimore, Md. : 1950) 182(5):3310-7, 2009 Mar 1 - Who cited this? | PubMed ID: 19234230 | Fulltext
Recommend
A novel BH3 ligand that selectively targets Mcl-1 reveals that apoptosis can proceed without Mcl-1 degradation.
+ cite this
+ View Abstract
Lee EF, Czabotar PE, van Delft MF, Michalak EM, Boyle MJ, Willis SN, Puthalakath H, Bouillet P, Colman PM, Huang DC, and Fairlie WD
The Journal of cell biology 180(2):341-55, 2008 Jan 28 - Who cited this? | PubMed ID: 18209102 | Fulltext
Recommend
Interleukin 15-mediated survival of natural killer cells is determined by interactions among Bim, Noxa and Mcl-1.
+ cite this
+ View Abstract
Huntington ND, Puthalakath H, Gunn P, Naik E, Michalak EM, Smyth MJ, Tabarias H, Degli-Esposti MA, Dewson G, Willis SN, Motoyama N, Huang DC, Nutt SL, Tarlinton DM, and Strasser A
Nature immunology 8(8):856-63, 2007 Aug - Who cited this? | PubMed ID: 17618288 | Fulltext
Recommend
Apoptosis initiated when BH3 ligands engage multiple Bcl-2 homologs, not Bax or Bak.
+ cite this
+ View Abstract
Willis SN, Fletcher JI, Kaufmann T, van Delft MF, Chen L, Czabotar PE, Ierino H, Lee EF, Fairlie WD, Bouillet P, Strasser A, Kluck RM, Adams JM, and Huang DC
Science (New York, N.Y.) 315(5813):856-9, 2007 Feb 9 - Who cited this? | PubMed ID: 17289999 | Fulltext
Recommend
The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized.
+ cite this
+ View Abstract
van Delft MF, Wei AH, Mason KD, Vandenberg CJ, Chen L, Czabotar PE, Willis SN, Scott CL, Day CL, Cory S, Adams JM, Roberts AW, and Huang DC
Cancer cell 10(5):389, 2006 Nov - Who cited this? | PubMed ID: 17097561 | Fulltext
Recommend
CD45 links the B cell receptor with cell survival and is required for the persistence of germinal centers.
+ cite this
+ View Abstract
Huntington ND, Xu Y, Puthalakath H, Light A, Willis SN, Strasser A, and Tarlinton DM
Nature immunology 7(2):190-8, 2006 Feb - Who cited this? | PubMed ID: 16378097 | Fulltext
Recommend
Life in the balance: how BH3-only proteins induce apoptosis.
+ cite this
+ View Abstract
Willis SN and Adams JM
Current opinion in cell biology 17(6):617-25, 2005 Dec - Who cited this? | PubMed ID: 16243507 | Fulltext
Recommend
Proapoptotic Bak is sequestered by Mcl-1 and Bcl-xL, but not Bcl-2, until displaced by BH3-only proteins.
+ cite this
+ View Abstract
Willis SN, Chen L, Dewson G, Wei A, Naik E, Fletcher JI, Adams JM, and Huang DC
Genes & development 19(11):1294, 2005 Jun 1 - Who cited this? | PubMed ID: 15901672 | Fulltext
Recommend
Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function.
+ cite this
+ View Abstract
Chen L, Willis SN, Wei A, Smith BJ, Fletcher JI, Hinds MG, Colman PM, Day CL, Adams JM, and Huang DC
Molecular cell 17(3):393, 2005 Feb 4 - Who cited this? | PubMed ID: 15694340 | Fulltext
Recommend



Search Google Scholar for Willis SN

Join Labmeeting

  • Organize and search your PDF collection
  • Collect papers
  • Search millions of papers
  • Keep up to date with paper alerts
  • Read your papers from anywhere
  • Recommend papers to colleagues
  • Manage your lab
Sign Up

Join Labmeeting

Labmeeting is a web service for researchers. Sign up with your academic email address.

Individuals or corporations not affiliated with an academic institution can request a trial subscription.